Barostim Neo [Image from CVRx]
Barostim
CVRx
CVRx’s Barostim Neo is a heart failure neuromodulation device.
Minneapolis-based CVRx designed the device to improve symptoms in patients with advanced heart failure who are not suited for other heart failure devices by electrically activating the baroreflex to reduce sympathetic activity and increase parasympathetic activity.
The device won FDA approval in August 2019 and was approved on the PMA pathway and earned breakthrough device designation in 2015.
